Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 712 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK December 21, 2020 Spotlight On: Exercise Physiologists in Cancer Care November 16, 2023 Opinion: ‘Beating cancer means beating it for everyone’ January 29, 2021 Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens... February 23, 2023 Load more HOT NEWS For Esophageal Cancer, Immunotherapy Likely to Play Larger Role Crazy Bride Called Off Her Wedding Because Her Guests Refused To... ESMO Releases New Patient Guide in Hepatocellular Carcinoma Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus...
